Corporate Tech Investors

NantKwest

NantKwest is a corporate VC investing group that partners with companies that are a good strategic fit.

Venture Investor Overview

Contact Information

Background Information

Overview

NantKwest (Nasdaq: NK), is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body's first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

4/6/2017

Transaction History

Our records indicate that NantKwest invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Chief Executive Officer

Patrick Soon-Shiong

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

NantKwest has invested in only one tech company, according to our database records. If we are missing a portfolio company, please let us know.

Browse more corporate investors:

Nagase America Corporation | NantMobile

Share this article

About Our Database of Corporate Tech Investors

This corporate tech investor profile is powered by VentureDeal.com, a leading supplier of corporate VC funding data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary